drugset
drugset / Trial / NCT00846157

Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients

NCT00846157 ↗

Phase 3 Unknown 276 enrolled NKBio Co.Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

Primary objective: * To compare the event free survival for 3years of R-CHOP plus Biocell Natural Killer Cell to R-CHOP therapy with DLBCL patients.

Timeline

Start
2007-09
Primary completion
2011-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator NKM Cell therapy 100 mg Intravenous

Indications

diffuse large B-cell lymphoma